Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients.
Joseph Edgar BlaisXuxiao YeEric Yuk Fai WanWilliam Chi Wai WongIan Chi Kei Ck WongChristopher Wai Kei LamEsther Wai Yin ChanPublished in: Clinical drug investigation (2022)
The results of this study showed better population-level effectiveness of simvastatin compared with gemfibrozil for the primary prevention of MACE; however, a definitive randomized controlled trial is required to compare simvastatin with gemfibrozil among patients with low HDL cholesterol, as they appear to obtain benefit with gemfibrozil.
Keyphrases
- randomized controlled trial
- cardiovascular events
- primary care
- end stage renal disease
- coronary artery disease
- systematic review
- newly diagnosed
- ejection fraction
- study protocol
- cardiovascular disease
- chronic kidney disease
- prognostic factors
- type diabetes
- patient reported outcomes
- squamous cell carcinoma
- clinical trial
- low density lipoprotein